Dejan Munjiza
Research Subjects
Dejan Munjiza has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Andrej Ilankovic
Center of Clinical Neurophysiology & Sleep Research, University Psychiatric Clinic, Pasterova 2, 11000 Belgrade, Serbia,
1 shared publication - Dejan Simeunović1 shared publication
- Jelisaveta Vuletić1 shared publication
- Milovan Petrovic
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
1 shared publication - Nikola Vojvodić
Neurology Clinic University Clinical Center of Serbia Belgrade Serbia
1 shared publication - Petar Otasevic
Dedinje Cardiovascular Institute, 11000 Belgrade, Serbia
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 7 (3) , 352-364
Insomnia as a risk factor in cardiac patients and the treatment approach
Introduction/Objective: Insomnia is a common sleep disorder that extends beyond the subjective feeling of poor sleep and represents a state of persistent physiological hyperarousal with important cardiovascular consequences. This review aimed to summarize the pathophysiological links between insomnia and cardiovascular disease and to compare the clinical implications of benzodiazepines and Z-hypnotics in the treatment of insomnia in cardiac patients. Methods: Using a descriptive-comparative approach, we analyzed review articles, meta-analyses, cohort studies, and observational studies addressing the relationship between insomnia, cardiovascular outcomes, and pharmacological treatment, with particular focus on differences between benzodiazepines and Z-hypnotics in cardiac patients. Results: The available evidence indicates that insomnia, through autonomic, neuroendocrine, inflammatory, and metabolic dysregulation, contributes to the development of hypertension, atrial fibrillation, and heart failure, with the greatest risk observed in insomnia with objectively short sleep duration. Longitudinal studies further suggest that persistent insomnia symptoms are associated with greater cardiovascular burden. In therapeutic terms, benzodiazepines in cardiac patients are associated with higher rates of adverse events, including heart failure rehospitalization, sudden cardiac arrest, and cardiovascular mortality, whereas available data on Z-hypnotics suggest a more favorable or neutral profile. Conclusion: Insomnia is a clinically important yet often overlooked cardiovascular risk factor. In cardiac patients, its recognition and treatment should be part of a comprehensive clinical approach, prioritizing non-pharmacological measures and carefully selected pharmacotherapy. When drug treatment is necessary, Z-hypnotics may be considered a more favorable alternative to benzodiazepines, with zopiclone standing out because of its pharmacological and clinical characteristics.
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 7 (3) , 352-364
Open AccessInsomnia as a risk factor in cardiac patients and the treatment approach
Introduction/Objective: Insomnia is a common sleep disorder that extends beyond the subjective feeling of poor sleep and represents a state of persistent physiological hyperarousal with important cardiovascular consequences. This review aimed to summarize the pathophysiological links between insomnia and cardiovascular disease and to compare the clinical implications of benzodiazepines and Z-hypnotics in the treatment of insomnia in cardiac patients. Methods: Using a descriptive-comparative approach, we analyzed review articles, meta-analyses, cohort studies, and observational studies addressing the relationship between insomnia, cardiovascular outcomes, and pharmacological treatment, with particular focus on differences between benzodiazepines and Z-hypnotics in cardiac patients. Results: The available evidence indicates that insomnia, through autonomic, neuroendocrine, inflammatory, and metabolic dysregulation, contributes to the development of hypertension, atrial fibrillation, and heart failure, with the greatest risk observed in insomnia with objectively short sleep duration. Longitudinal studies further suggest that persistent insomnia symptoms are associated with greater cardiovascular burden. In therapeutic terms, benzodiazepines in cardiac patients are associated with higher rates of adverse events, including heart failure rehospitalization, sudden cardiac arrest, and cardiovascular mortality, whereas available data on Z-hypnotics suggest a more favorable or neutral profile. Conclusion: Insomnia is a clinically important yet often overlooked cardiovascular risk factor. In cardiac patients, its recognition and treatment should be part of a comprehensive clinical approach, prioritizing non-pharmacological measures and carefully selected pharmacotherapy. When drug treatment is necessary, Z-hypnotics may be considered a more favorable alternative to benzodiazepines, with zopiclone standing out because of its pharmacological and clinical characteristics.